Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms IY-IY-PEG5-nutlin |
Target |
Action degraders |
Mechanism TrkC degraders(Neurotrophic tyrosine kinase receptor type 3 degraders) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC96H130Cl2N24O17 |
InChIKeyDVJPBSSBZSLKFD-LMBYOWTGSA-N |
CAS Registry- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Triple Negative Breast Cancer | Preclinical | United States | 12 Sep 2019 |





